The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > BUSINESS
BUSINESS
- AZ’s Ex-Japan Chief Fredrickson Picked as Global Head of Oncology
October 18, 2017
- Durvalumab Improves PFS in Japanese NSCLC Patients
October 17, 2017
- Tagrisso Significantly Extends PFS in Japanese EGFRm NSCLC Patients
October 17, 2017
- Nobelpharma Plans to File Sakigake-Designated Topical Sirolimus; Application Expected Later this Month
October 17, 2017
- Japan’s Oncology Market Estimated to Reach Over 1.4 Trillion Yen in 2025: Fuji Keizai
October 17, 2017
- Ethical Drug Sales Up 2.2% in August, Keytruda Upbeat: Crecon
October 17, 2017
- Naldemedine Now Available in US: Shionogi
October 16, 2017
- Takeda Looks to House 3,000 Researchers at Shonan Innovation Park, Create Fund by March
October 16, 2017
- Eisai to Acquire Marketing Authorization for Kolbet from Toyama Chemical on Jan. 1
October 16, 2017
- Novartis Not to Conduct Additional Japan Study of Ribociclib, While PIb Study Underway in Asian Countries including Japan
October 16, 2017
- Sanwa Kagaku to Reduce 150 Jobs as Part of Suzuken Group’s SGA Cost Cutting Efforts
October 16, 2017
- JT Wins Japan Commercialization Rights for Calcifediol Extended-Release Capsules
October 16, 2017
- Kowa Wins Livalo Patent Suit against Towa
October 13, 2017
- Meiji Grants Carbapenem Rights to Spero Outside Japan, Asia
October 13, 2017
- Teijin Earns Japan Rights to Novel Botulinum Toxin
October 13, 2017
- Ono Grabs Rights to 2 XPO1 Inhibitors in Japan, Asia
October 13, 2017
- Daiichi Sankyo Initiates AMED-Funded Joint Research on Genetic Vaccine Platform with NIBIOHN
October 13, 2017
- LEO Pharma to Offer Cell Assays in Japan to Evaluate External Compounds under Unique Open Innovation Model
October 13, 2017
- FGF23 Antibody Burosumab Earns FDA Priority Status: Kyowa Kirin/Ultragenyx
October 12, 2017
- FDA Fast-Tracks Astellas’s AML Med Gilteritinib
October 12, 2017
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…